Wu H.-Y.KUAN-YU HUNGYU-KANG TUKUO-LIONG CHIEN2021-08-202021-08-2020142042-6305https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903581837&doi=10.2217%2fcer.14.10&partnerID=40&md5=67bbc768f01944aac379365447cb7ce9https://scholars.lib.ntu.edu.tw/handle/123456789/578467angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; Bayes' theorem; diabetes mellitus; drug combinations[SDGs]SDG3alpha adrenergic receptor blocking agent; angiotensin receptor antagonist; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; creatinine; dipeptidyl carboxypeptidase inhibitor; diuretic agent; placebo; angiotensin receptor antagonist; antihypertensive agent; dipeptidyl carboxypeptidase inhibitor; Bayes theorem; blood pressure regulation; cardiometabolic risk; comorbidity; comparative effectiveness; diabetes mellitus; diabetic nephropathy; diabetic patient; dialysis; human; hypertension; insulin dependent diabetes mellitus; meta analysis (topic); mortality; non insulin dependent diabetes mellitus; priority journal; renal protection; renin angiotensin aldosterone system; review; comparative effectiveness; complication; Diabetes Complications; risk factor; treatment outcome; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypertension; Risk Factors; Treatment Outcomereview10.2217/cer.14.10249691442-s2.0-84903581837